We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

L:TSXLoblaw Companies Limited Analysis

Data as of 2026-03-10 - not real-time

CA$63.40

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Loblaw (L.TO) is trading at C$63.4, comfortably above its 20‑day SMA of 65.45 and the 50‑day SMA of 63.86, while the 200‑day SMA sits at 58.90. The RSI of 45.5 indicates a neutral stance, but the MACD histogram is negative and the signal line is bearish, suggesting short‑term downside pressure. Volatility over the past 30 days is high at roughly 30% and beta is slightly negative (-0.12), reflecting limited correlation with broader market moves. The stock’s PE of 30.0x and price‑to‑book of 6.7x place it above peers, and the DCF‑derived fair value of C$53.95 implies it is currently overvalued.
On the fundamentals side, revenue grew nearly 10% YoY, operating margins are modest at 6.9%, and free cash flow remains healthy at roughly C$3.8 bn. A dividend yield of 0.89% with a low payout ratio of 26% supports sustainability, while a high debt‑to‑equity of 145% raises leverage concerns. Recent news of a C$2.4 bn investment to modernize stores and a 10.9% earnings per share increase in Q4 provide a growth catalyst, yet the share price has slipped from the recent high of C$68.16, underscoring the valuation gap.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Recent C$2.4 bn store expansion announcement
  • Technical support around C$61.5 and bearish MACD
  • Neutral RSI and elevated short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Steady revenue growth (~9.6%) and solid free cash flow
  • Low dividend payout ratio indicating sustainability
  • High leverage (debt‑to‑equity >140%) tempering upside

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Defensive consumer‑staples positioning with strong brand equity
  • Consistent cash generation supporting dividend and reinvestment
  • Long‑term growth opportunities from store modernization and digital channels

Key Metrics & Analysis

Financial Health

Revenue Growth9.60%
Profit Margin4.17%
P/E Ratio30.0
ROE23.17%
ROA6.78%
Debt/Equity145.68
P/B Ratio6.7
Op. Cash FlowCA$6.3B
Free Cash FlowCA$3.8B

Technical Analysis

TrendBullish
RSI45.5
SupportCA$61.52
ResistanceCA$69.59
MA 20CA$65.45
MA 50CA$63.86
MA 200CA$58.90
MACDBearish
VolumeIncreasing
Fear & Greed Index78.66

Valuation

Fair ValueCA$53.95
Target PriceCA$68.45
Upside/Downside7.97%
GradeOvervalued
TypeGrowth
Dividend Yield0.89%

Risk Assessment

Beta-0.12
Volatility29.78%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.